Biosimilars

Commented by Tarik Dede on October 30th, 2026 | 13:54 CET

Pharma as a defensive alternative: Eli Lilly, Formycon and GSK in focus

• Pharma
• Health
• Weight-loss injection
• Generics
• GSK
• Formycon
• Biosimilars
• Eli Lilly

This year we have repeatedly seen major rotations, particularly in the US equity markets. When AI stocks weakened, other sectors, such as utilities and pharma, performed well. No real money was withdrawn from the markets in the process. Pharma stocks could be among the big winners if the major indices suffer a serious crash. An end to the AI boom, for example, would be a disaster for investors and market participants. Investors looking to gradually adopt a more defensive position should consider adding healthcare stocks to their portfolio. In the past, this strategy has certainly often proved its worth. Today we therefore look at the shares of Formycon, Eli Lilly and GSK.